Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347159 · ClinicalTrials.gov registry record · Phase 2

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

A Phase 2 study of Hypertrophic Cardiomyopathy, sponsored by Edgewise Therapeutics.

Active
Registry status
Phase 2
Development phase
100
Enrollment target
20
Study locations

NCT06347159 is a Phase 2 study of Hypertrophic Cardiomyopathy that is active but no longer recruiting, run by Edgewise Therapeutics. The registered enrollment target is 100 participants, below the 1,341-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347159, a Phase 2 study of Hypertrophic Cardiomyopathy, is active but no longer recruiting, sponsored by Edgewise Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

Conditions Studied

Hypertrophic Cardiomyopathy

Interventions

  • DRUG EDG-7500

Study Locations (20)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Brigham and Womens Hospital - Boston
  • Lahey Hospital and Medical Center - Burlington

Ohio

  • The Lindner Research Center at Christ Hospital - Cincinnati
  • University Hospitals Cleveland Medical Center - Cleveland
  • Cleveland Clinic - Cleveland

California

  • University of California, San Francisco - San Francisco
  • Stanford University Hospital / Stanford Health Care - Stanford

New York

  • North Shore University Hospital - Manhasset
  • NYU Langone Health Medical Center - HCM Program Office (Study open to existing NYU patients only) - New York

North Carolina

  • Sanger Heart and Vascular Institute - Charlotte
  • Duke Health Center Arringdon - Morrisville

Georgia

  • Emory Clinic - Atlanta

Michigan

  • Michigan Medicine - Michigan Clinical Research Unit - Ann Arbor

Missouri

  • Saint Luke's Hospital of Kansas City - Kansas City

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-04-11
Est. Completion 2026-12
Phase Phase 2

Sponsor

Edgewise Therapeutics

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06347159

The ClinicalTrials.gov registry entry for NCT06347159 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,341-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (93% lower). The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which EDG-7500 is the first listed.

NCT06347159 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT06347159 about?

NCT06347159 is a clinical study titled "A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)". This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).

What is the current status of trial NCT06347159?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-04-11. Estimated completion is 2026-12.

What conditions does trial NCT06347159 study?

This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy.

What interventions are being tested in trial NCT06347159?

The interventions under investigation include: EDG-7500 (DRUG).

Who is sponsoring clinical trial NCT06347159?

This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347159 being conducted?

This trial has 20 study locations across California, Georgia, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertrophic Cardiomyopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertrophic Cardiomyopathy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.